Participants received either 1,332 mg/day or 1,998 mg/day, depending on their weight, for 30 days; however, there was no placebo control group (Gualtieri et al., 2011). Acamprosate was well tolerated, improving alcohol craving and relapses while reducing protracted withdrawal symptom severity measured using the Clinical Institute Withdrawal Assessment for Alcohol (Gualtieri et al., 2011). We […]